Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.
Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.